14-day Premium Trial Subscription Try For FreeTry Free
$4.56
-0.220 (-4.60%)
At Close: May 07, 2024
Forecast Earnings Dividends Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $0.0060 $169.56 Tuesday, 7th May 2024 ABEO stock ended at $4.56. This is 4.60% less than the trading day before Monday, 6th May 2024. During the day the stock fluctuated 11.56% from a day low at $4.54 to a day high of $5.07.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical Abeona Therapeutics Inc. prices

Date Open High Low Close Volume
Dec 02, 2013 $0.300 $0.300 $0.260 $0.300 20 000
Nov 29, 2013 $0.290 $0.300 $0.290 $0.300 50 000
Nov 27, 2013 $0.260 $0.290 $0.260 $0.290 45 000
Nov 26, 2013 $0.280 $0.300 $0.250 $0.300 60 000
Nov 25, 2013 $0.290 $0.300 $0.270 $0.300 45 000
Nov 22, 2013 $0.290 $0.300 $0.280 $0.300 220 000
Nov 21, 2013 $0.300 $0.300 $0.280 $0.300 10 000
Nov 20, 2013 $0.300 $0.300 $0.280 $0.300 35 000
Nov 19, 2013 $0.300 $0.320 $0.290 $0.300 5 000
Nov 18, 2013 $0.280 $0.320 $0.280 $0.320 65 000
Nov 15, 2013 $0.320 $0.320 $0.290 $0.300 60 000
Nov 14, 2013 $0.320 $0.320 $0.300 $0.320 15 000
Nov 13, 2013 $0.320 $0.320 $0.300 $0.320 35 000
Nov 12, 2013 $0.320 $0.320 $0.300 $0.320 20 000
Nov 11, 2013 $0.330 $0.330 $0.310 $0.330 0
Nov 08, 2013 $0.300 $0.330 $0.300 $0.330 85 000
Nov 07, 2013 $0.300 $0.320 $0.300 $0.320 10 000
Nov 06, 2013 $0.310 $0.330 $0.300 $0.330 80 000
Nov 05, 2013 $0.320 $0.340 $0.320 $0.340 65 000
Nov 04, 2013 $0.310 $0.340 $0.310 $0.330 30 000
Nov 01, 2013 $0.320 $0.340 $0.300 $0.340 60 000
Oct 31, 2013 $0.320 $0.320 $0.300 $0.320 40 000
Oct 30, 2013 $0.320 $0.350 $0.320 $0.350 0
Oct 29, 2013 $0.330 $0.350 $0.310 $0.350 65 000
Oct 28, 2013 $0.320 $0.330 $0.320 $0.330 15 000
Click to get the best stock tips daily for free!

About Abeona Therapeutics Inc.

Abeona Therapeutics. Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease;... ABEO Profile

Golden Star

Ticker Date Change Price
VCSH May 03 0.0130% $76.93
BNDX May 03 0.349% $48.68
BBCA May 03 1.26% $65.44
ISTB May 03 0.0425% $47.11
ADTH May 03 5.56% $3.24
WMT May 03 1.34% $59.82
UNP May 03 0.84% $240.36
INGR May 03 1.75% $114.56
ASH May 03 2.26% $95.85
WU May 03 0.449% $13.37
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT